Can a drug and heat combo beat a parasitic skin disease?
NCT ID NCT04268524
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial tests whether a drug called miltefosine, heat therapy (thermotherapy), or both together can safely and effectively treat skin lesions caused by the Leishmania tropica parasite in Pakistan. About 645 adults with up to four skin sores will be randomly assigned to one of four treatment groups and followed for several months. The goal is to see if these newer approaches work as well as or better than the current standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- miltefosine combined with thermotherapy (heat treatment)
- What this could lead to
- If successful, this could offer simpler, safer treatment options for a disfiguring skin disease, reducing reliance on painful injections.
- What could go wrong
- This is an early-stage trial in a single country, and the combination therapy may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLD WORLD CUTANEOUS LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bolan Medical Complex Hospital
Quetta, Balochistan, Pakistan
-
Kuchlak Primary Health Care Centre (MCH), Kuchlak, Pakistan
Quetta, Balochistan, Pakistan
-
Shaheed Mohtarma Benazir Bhutto General Hospital
Quetta, Balochistan, Pakistan